To explore the clinical application of ursodeoxycholic acid combined with glutathione in the treatment of cholestatic liver disease(CLD) and its impact on liver fibrosis.
A total of 151 patients with CLD who were treated at Shanxi Fenyang Hospital from December 2021 to January 2024 were selected and divided into the control group(75 cases, treated with adenosine methionine combined with glutathione) and the observation group(76 cases,treated with ursodeoxycholic acid combined with glutathione). The clinical efficacy, liver fibrosis indicators, liver function, bile acid indicators, Child-Pugh classification changes, and adverse reactions were compared between the two groups.
After treatment, the total effective rate of the observation group was higher than that of the control group, with a significant difference(92.11% vs. 80.00%, P<0.05). After treatment, the levels of type III procollagen, laminin, type Ⅳ collagen, and hyaluronic acid in both groups were lower than those before treatment(P<0.05). The levels in the observation group were lower than those in the control group(P<0.05). The levels of total bilirubin, alanine aminotransferase, and aspartate aminotransferase in both groups were lower than those before treatment, and the levels in the observation group were lower than those in the control group(P<0.05). The levels of bile acids and cholylglycine in both groups were lower than those before treatment, and the levels in the observation group were lower than those in the control group(P<0.05). The Child-Pugh classification in both groups showed improvement and the improvement degree in the observation group was better than that in the control group(P<0.05). The adverse reactions were mainly nausea, vomiting, abdominal distension, liver pain, and decreased platelet count, but the differences were not statistically significant(P>0.05).
The combination of ursodeoxycholic acid and glutathione can exert a synergistic effect,effectively reverse the process of liver fibrosis, significantly improve liver synthesis and metabolism, and provide a better treatment option for CLD patients.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |